Year All202320222021 Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023 06-03-2023 Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results 05-15-2023 Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023 05-10-2023 Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023 05-09-2023 Zevra Announces Board of Directors and Leadership Changes 05-08-2023 Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy 05-03-2023 Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy 04-17-2023 Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy 04-04-2023 Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors 03-30-2023 Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders 03-15-2023
Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023 06-03-2023
Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023 05-10-2023
Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy 04-17-2023
